Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Definition Statement

This document provides information on the four types of written products developed under the auspices of the AUA.

Download Definition Statement PDF

CLINICAL PRACTICE GUIDELINE (CPG)

DEFINITION
Strong, Moderate, or Conditional Recommendations based on available scientific evidence with consideration for balance of risks/benefits; further information provided in the form of Clinical Principle or Expert Opinion statements where gaps in the evidence exist

LEVEL OF EVIDENCE
Systematic reviews; RCTs supplemented with lower level evidence and expert consensus when available high-quality evidence is lacking

COMPOSITION OF DEVELOPMENT GROUP
Multidisciplinary subject matter experts, including patients/patient advocates, as appropriate

EXTERNAL REVIEW
Extensive review process to include all stakeholders, relevant approval bodies (PGC, S&Q, BOD), and public comment

REVIEW CYCLE
24-36 months or on an ad hoc basis as determined by the PGC

DOCUMENT SUNSETTING
10 years or as determined by the PGC

EXAMPLE DOCUMENT
Advanced Prostate Cancer

QUALITY IMPROVEMENT ISSUE BRIEF (QIIB)

DEFINITION
Qualitative assessments on quality or patient safety topics in Urology—these may provide a brief explanation of an available technology; summarize an AUA-sponsored conference, congress, symposium, or other meeting; discuss case studies in QI; and/or discuss a particular theoretical or practical approach in quality, safety, and/or measurement

LEVEL OF EVIDENCE
Expert opinion supported by available literature

COMPOSITION OF DEVELOPMENT GROUP
Subject matter experts in the topic area

EXTERNAL REVIEW
Review by relevant stakeholders and approval bodies (QIPS, S&Q, BOD), and public comment (except meeting summaries)

REVIEW CYCLE
Every two years, or on an ad hoc basis, as determined by the QIPS Committee

DOCUMENT SUNSETTING
10 years or as determined by S&Q and/or QIPS

EXAMPLE DOCUMENT
Implementation of Shared Decision Making into Urological Practice

CLINICAL CONSENSUS STATEMENT (CCS)

DEFINITION
Statements of expert opinion for which there may or may not be supporting evidence available in the medical literature

LEVEL OF EVIDENCE
Expert opinion supported by available literature

COMPOSITION OF DEVELOPMENT GROUP
Subject matter experts and others with interest in topic area

EXTERNAL REVIEW
Review by relevant stakeholders and approval bodies (QIPS, S&Q, BOD), and public comment

REVIEW CYCLE
Every two years, or on an ad hoc basis, as determined by the QIPS Committee

DOCUMENT SUNSETTING
10 years or as determined by S&Q and/or QIPS

EXAMPLE DOCUMENT
Urologic Procedures and Antimicrobial Prophylaxis

POLICY/POSITION STATEMENTS (PPS)*

DEFINITION
Presents the AUA positions, philosophy and/or policies on a topic of interest in the urology specialty

LEVEL OF EVIDENCE
Literature review; panel members review the literature and contribute practical knowledge and experience to conclusions

COMPOSITION OF DEVELOPMENT GROUP
Subject matter experts in the topic area

EXTERNAL REVIEW
Review by relevant stakeholders and approval bodies (QIPS, S&Q, BOD)

REVIEW CYCLE
Every year, or on an ad hoc basis, as determined by the QIPS or Public Policy Committees

DOCUMENT SUNSETTING
10 years or as determined by S&Q and/or QIPS or Public Policy

EXAMPLE DOCUMENT
Beers Criteria for Potentially Inappropriate Medication

*PPSs of non-BOD origin

advertisement

advertisement